drugset
drugset / Trial / NCT04480827

Open-Label Study to Evaluate the Safety, Tolerability, and PK of Aramchol in Subjects With Hepatic Impairment

NCT04480827 ↗

Phase 1 Completed 57 enrolled Galmed Research and Development, Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Phase 1, multicenter, open-label, 2-part, single- and multiple-dose study designed to assess the effect of hepatic insufficiency on the PK of aramchol

Timeline

Start
2020-02-13
Primary completion
2022-03-24
Completion
2022-03-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Aramchol Other / unclassified 300 mg —
Subject Aramchol Other / unclassified 600 mg —

Indications

No indication recorded.